H. Akaza

发表

Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images.

T. Miyagawa, M. Tsutsumi, T. Matsumura, 2009, Japanese journal of clinical oncology.

Tissue elasticity imaging for diagnosis of prostate cancer: A preliminary report

N. Miyanaga, H. Akaza, M. Yamakawa, 2005, International journal of urology : official journal of the Japanese Urological Association.

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.

Yusuke Nakamura, Tatsuhiko Tsunoda, Hidewaki Nakagawa, 2007, Cancer research.

A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.

S. Saga, R. Ueda, H. Akaza, 2011, Oncology reports.

Overall survival and good tolerability of long‐term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma

H. Akaza, M. Murai, S. Naito, 2011, BJU international.

Sorafenib‐associated hand–foot syndrome in Japanese patients

J. Furuse, H. Akaza, M. Murai, 2011, The Journal of dermatology.

Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness

H. Akaza, 2011, Cancer science.

Current status of chemotherapy in risk‐adapted management for metastatic testicular germ cell cancer

H. Akaza, K. Kawai, 2010, Cancer science.

Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.

T. Miki, H. Akaza, O. Ogawa, 2008, Japanese journal of clinical oncology.

Identification of a type III secretion system in uropathogenic Escherichia coli.

H. Akaza, J. Miyazaki, H. Hayashi, 2002, FEMS microbiology letters.

Blood isoflavone levels during intake of a controlled hospital diet.

N. Miyanaga, H. Akaza, Naomi Takashima, 2004, Journal of nutritional science and vitaminology.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

F. Saad, B. Tombal, H. Akaza, 2020, The New England journal of medicine.

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

S. Hitier, H. Akaza, G. Facchini, 2018, Journal of global oncology.

Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.

C. Porta, A. Ravaud, M. Gore, 2012, Cancer Treatment Reviews.

Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma.

H. Akaza, M. Harada, K. Hattori, 1995, British journal of urology.

Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer

H. Akaza, K. Izumi, Y. Kitagawa, 2016, World Journal of Urology.

Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy

H. Nishiyama, H. Akaza, K. Kawai, 2014, International journal of urology : official journal of the Japanese Urological Association.

Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

H. Nishiyama, H. Akaza, T. Kojima, 2015, Journal of Cancer Research and Clinical Oncology.

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score

H. Akaza, O. Ogawa, M. Murai, 2013, Prostate international.

Hormonal therapy for prostate cancer: Current topics and future perspectives

Y. Homma, H. Akaza, K. Kihara, 2010, International journal of urology : official journal of the Japanese Urological Association.

Combined androgen blockade with bicalutamide for advanced prostate cancer

H. Akaza, S. Naito, H. Kanetake, 2009, Cancer.

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

T. Deguchi, Y. Ohashi, H. Akaza, 2008, Journal of Cancer Research and Clinical Oncology.

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

Y. Ohashi, H. Akaza, S. Naito, 2007, Prostate Cancer and Prostatic Diseases.

A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5‐year follow‐up

Y. Homma, Y. Ohashi, H. Akaza, 2003, BJU international.

Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model.

H. Akaza, T. Shirai, K. Kawai, 2006, The Journal of urology.

[TNM classification].

H. Akaza, H Akaza, 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Axitinib for the treatment of advanced renal cell carcinoma

H. Akaza, T. Fukuyama, 2014, Expert opinion on pharmacotherapy.

INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?

D. Lamm, H. Akaza, T. Shinka, 1995, International journal of urology : official journal of the Japanese Urological Association.

Decreased expression of α‐catenin is associated with poor prognosis of patients with localized renal cell carcinoma

J. Schalken, H. Akaza, F. Debruyne, 1997 .

Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective

H. Akaza, 2006, Cancer science.

The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

H. Akaza, O. Ogawa, M. Murai, 2006, The Journal of urology.

Incidence of venous thromboembolism following major abdominal surgery: a multi‐center, prospective epidemiological study in Japan

Y. Maehara, H. Akaza, M. Sakon, 2006, Journal of thrombosis and haemostasis : JTH.

Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma.

H. Akaza, T. Kojima, T. Shimazui, 2006, Oncology reports.

Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.

T. Ochiya, H. Akaza, T. Sekiya, 2000, Carcinogenesis.

Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model.

H. Nishiyama, H. Akaza, Takashi Nakamura, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Nanoparticulation of BCG-CWS for application to bladder cancer therapy.

H. Nishiyama, H. Akaza, Toshihiro Ito, 2014, Journal of controlled release : official journal of the Controlled Release Society.

High Rate of Induction of Human Autologous Cytotoxic T Lymphocytes against Renal Carcinoma Cells Cultured with an Interleukin Cocktail

H. Akaza, K. Saijo, K. Kawai, 1998, Japanese journal of cancer research : Gann.

Phase I/II clinical trials of carbon ion therapy for prostate cancer

H. Akaza, H. Tsujii, K. Akakura, 2004, The Prostate.

Dietary isoflavones may protect against prostate cancer in Japanese men.

N. Miyanaga, H. Akaza, S. Naito, 2007, The Journal of nutrition.

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

D. Lamm, J. Witjes, M. Colombel, 2008 .

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

H. Akaza, M. Shiota, S. Naito, 2020, International journal of urology : official journal of the Japanese Urological Association.

Prostate cancer trends in Asia

H. Akaza, S. Hinotsu, M. Onozawa, 2017, World Journal of Urology.

S&T-20 VALIDATION OF TNM CLASSIFICATION FOR METASTATIC PROSTATIC CANCER TREATED USING PRIMARY ANDROGEN DEPRIVATION THERAPY

H. Akaza, K. Izumi, Y. Kitagawa, 2016 .

Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy

H. Akaza, K. Izumi, Y. Kitagawa, 2016, World Journal of Urology.

A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer

H. Akaza, H. Koike, Kazuhiro Suzuki, 2014, Cancer Chemotherapy and Pharmacology.

Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.

M. Cooperberg, P. Carroll, H. Akaza, 2013, Japanese journal of clinical oncology.

Title Sixth joint meeting of J-Cap and CaPSURE-A multinational perspective on prostate cancer management and patient outcomes Permalink

M. Cooperberg, P. Carroll, H. Akaza, 2013 .

Correlation of Allelic Loss of the P53 Gene and Tumor Grade, Stage, and Malignant Progression in Bladder Cancer

K. Yamaguchi, M. Tsutsumi, H. Akaza, 1997, International journal of urology : official journal of the Japanese Urological Association.

Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience.

T. Miki, N. Miyanaga, H. Akaza, 2007, Japanese journal of clinical oncology.

Diabetes, hypertension, and manic episodes

H. Akaza, M. Odawara, K. Tada, 1996, The Lancet.

Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study

H. Akaza, T. Fukagai, M. Namiki, 2006, International journal of urology : official journal of the Japanese Urological Association.

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment

H. Akaza, M. Oya, K. Tatsugami, 2018, Oncotarget.

Union for International Cancer Control International Session: Healthcare Economics: The significance of the UN summit non‐communicable diseases political declaration in Asia

T. Masui, H. Akaza, J. Roh, 2013, Cancer science.

Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

H. Akaza, S. Naito, H. Fujimoto, 2010, Oncology.

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)

H. Akaza, Y. Kitagawa, A. Mizokami, 2017, Prostate international.

Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis

H. Akaza, K. Itoh, Masayuki Yamamoto, 2004, Cancer Research.

Does tumor size or microvascular invasion affect prognosis in patients with renal cell carcinoma?

T. Miyagawa, N. Miyanaga, H. Akaza, 2007, Japanese journal of clinical oncology.

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

H. Akaza, Y. Tomita, M. Fujisawa, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.

H. Akaza, Y. Tomita, M. Fujisawa, 2014, Japanese journal of clinical oncology.

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

H. Akaza, Y. Hamamoto, N. Tsuchiya, 2010, Japanese journal of clinical oncology.

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

H. Akaza, Y. Tomita, S. Naito, 2011, European journal of cancer.

Phase II study ofcis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract

T. Miki, H. Akaza, O. Yoshida, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract

T. Matsuda, T. Miki, H. Akaza, 2004, Cancer Chemotherapy and Pharmacology.

Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.

Y. Homma, Y. Ohashi, H. Akaza, 1999, Japanese journal of clinical oncology.

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria

K Koiso, S. Ishikawa, N. Miyanaga, 1999, International journal of urology : official journal of the Japanese Urological Association.

Evidence‐based clinical practice guidelines for bladder cancer (Summary – JUA 2009 Edition)

H. Nishiyama, N. Saijo, Y. Mizutani, 2010, International journal of urology : official journal of the Japanese Urological Association.

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

C. Roehrborn, Y. Lotan, A. Sagalowsky, 2006, The Journal of urology.

Chemopreventive effects of cyclooxygenase‐2 inhibitor and epidermal growth factor‐receptor kinase inhibitor on rat urinary bladder carcinogenesis

H. Akaza, R. Oyasu, K. Hattori, 2006, BJU international.

Serum Isoflavone Concentrations and Equol-Producing Intestinal Flora inProstate Cancer in Japanese-American in Hawaii

G. Maskarinec, H. Akaza, T. Namiki, 2016 .

Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk.

H. Akaza, T. Yamashita, A. Yoneta, 2013, Asian Pacific journal of cancer prevention : APJCP.

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Y. Ohashi, H. Akaza, M. Oya, 2016, International Journal of Clinical Oncology.

Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer

N. Miyanaga, H. Akaza, K. Kawai, 2004, International journal of urology : official journal of the Japanese Urological Association.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Current pathology keys of renal cell carcinoma.

H. Moch, V. Reuter, F. Algaba, 2011, European urology.

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

M. Gleave, J. Nelson, J. Moul, 2012, Cancer.

Higher consumption of green tea may enhance equol production.

N. Miyanaga, H. Akaza, T. Fujioka, 2003, Asian Pacific journal of cancer prevention : APJCP.

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

H. Akaza, K. Izumi, Y. Kitagawa, 2014, Journal of Cancer Research and Clinical Oncology.

Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10‐year follow‐up

Y. Homma, Y. Ohashi, H. Akaza, 2006, BJU international.

Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.

H. Akaza, O. Ogawa, M. Murai, 2004, Japanese journal of clinical oncology.

Prostate Cancer Working Group report.

H. Akaza, S. Horie, T. Fukagai, 2010, Japanese journal of clinical oncology.

Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer

H. Akaza, 2016, Current Urology Reports.

Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference☆

H. Akaza, P. Mainwaring, 2015, Prostate international.

P Prostate Cancer Chemoprevention Study : An investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen

N. Miyanaga, H. Akaza, T. Fujioka, 2011 .

Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers

N. Miyanaga, H. Akaza, N. Tanaka, 2009, Prostate Cancer and Prostatic Diseases.

Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration.

N. Miyanaga, H. Akaza, S. Naito, 2002, Japanese journal of clinical oncology.

Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2′-dimethyl-4-aminobiphenyl (DMAB)

H. Akaza, T. Shirai, A. Yamauchi, 2000, Prostate Cancer and Prostatic Diseases.

A five‐alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

H. Akaza, T. Shirai, M. Onozawa, 1998, Cancer.

Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan

H. Nishiyama, H. Akaza, K. Kawai, 2014, Prostate international.

Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men

N. Miyanaga, H. Akaza, K. Fujimoto, 2008, Prostate Cancer and Prostatic Diseases.

Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex.

H. Akaza, T. Shirai, K. Koiso, 1995, Journal of the National Cancer Institute.

Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries

H. Akaza, Jasmine Lim, M. Saad, 2021, Cancer science.

[Histopathological comparison of prostatic adenocarcinoma in Japan and the United States].

F. Mostofi, H. Akaza, M. Harada, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[Histopathological comparison of stage A prostatic adenocarcinoma in Japan and the United States].

H. Akaza, M. Harada, T. Shimazui, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Cross-boundary Cancer Studies at the University of Tokyo: View from the world of science and reason.

H. Akaza, 2014, Japanese journal of clinical oncology.

Validation of the prognostic grouping of the seventh edition of the tumor‐nodes‐metastasis classification using a large‐scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy

H. Nishiyama, H. Akaza, K. Kawai, 2013, International journal of urology : official journal of the Japanese Urological Association.

Current status and prospects of androgen depletion therapy for prostate cancer.

H. Akaza, 2008, Best practice & research. Clinical endocrinology & metabolism.

Global update on defining and treating high‐risk localized prostate cancer with leuprorelin: an Asian perspective

H. Akaza, Kazuto Ito, S. Ueno, 2007, BJU international.

Joint Symposium of Korean Cancer Association & UICC-ARO-Cross-boundary cancer studies: cancer and Universal Health Coverage (UHC) in Asia.

H. Akaza, J. Roh, E. Park, 2017, Japanese journal of clinical oncology.

Lectin‐reactive alpha‐fetoprotein as a marker for testicular tumor activity

N. Miyanaga, H. Akaza, T. Kojima, 2005, International journal of urology : official journal of the Japanese Urological Association.

A Case of Angiomyolipoma Diagnosed by Thin Slice Non‐Enhanced CT and Needle Biopsy

H. Akaza, K. Kawai, N. Sekido, 1996, International journal of urology : official journal of the Japanese Urological Association.

[Retroperitoneal liposarcoma with intrarenal metastases which was difficult to distinguish from angiomyolipoma. A case report].

H. Akaza, H. Shiraiwa, N. Sekido, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Asia prostate cancer study (A-CaP Study) launch symposium

M. Cooperberg, P. Carroll, D. Murphy, 2016, Prostate international.

Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi‐institutional Japan‐wide database

H. Kume, H. Akaza, M. Shiota, 2021, International journal of urology : official journal of the Japanese Urological Association.

A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study

H. Akaza, S. Horie, Y. Kakehi, 2021, Japanese journal of clinical oncology.

Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.

H. Akaza, Satoru Takahashi, A. Yokomizo, 2016, The Journal of urology.

Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats

T. Sugimura, H. Akaza, M. Baba, 1999, Japanese journal of cancer research : Gann.

Adjuvant goserelin improves clinical disease‐free survival and reduces disease‐related mortality in patients with locally advanced or localized prostate cancer

H. Akaza, H. Akaza, 2004, BJU international.

Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy

H. Akaza, Jasmine Lim, S. Hinotsu, 2020, Cancer medicine.

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy

H. Akaza, A. Yokomizo, T. Nakatani, 2014, Japanese journal of clinical oncology.

The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis

Tsuyoshi Shiina, Takeshi Matsumura, Masakazu Tsutsumi, 2007, International Journal of Clinical Oncology.

Effect of basic fibroblast growth factor incorporating gelatin microspheres on erectile function in the diabetic rat.

Y. Tabata, H. Akaza, T. Tsukamoto, 2005, The Journal of urology.

Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.

H. Akaza, K. Kawai, S. Hinotsu, 1998, Japanese journal of clinical oncology.

Long-Term Results of Donor-Specific Blood Transfusion with Cyclosporine in Living Related Kidney Transplantation

H. Akaza, Y. Takada, A. Koyama, 2001, Nephron.

Counts of Slackia sp. strain NATTS in intestinal flora are correlated to serum concentrations of equol both in prostate cancer cases and controls in Japanese men.

H. Akaza, N. Masumori, T. Miura, 2014, Asian Pacific journal of cancer prevention : APJCP.

Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS

N. Miyanaga, H. Akaza, K. Nomoto, 2010, Archives of Microbiology.

Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents.

A. Pantuck, N. Miyanaga, H. Akaza, 2004, Japanese journal of clinical oncology.

Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology.

S. Saga, H. Akaza, Kogenta Nakamura, 2006, International journal of oncology.

[Histopathological comparison of stage A prostatic adenocarcinoma in Japan and the United States].

H. Akaza, M. Harada, T. Shimazui, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[Antitumor effect of combined use of purified human natural tumor necrosis factor (N-TNF) and cis-diamminedichoroplatinum (II) (cisplatin) on the implanted bladder carcinoma (MBT-2) in mice].

N. Miyanaga, H. Akaza, K. Koiso, 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Surface antigen expression on bladder tumor cells induced by bacillus Calmette‐Guérin (BCG): A role of BCG internalization into tumor cells

H. Akaza, K. Kawai, N. Ikeda, 2002, International journal of urology : official journal of the Japanese Urological Association.

Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.

H. Akaza, T. Kakizoe, S. Hinotsu, 1998, Japanese journal of clinical oncology.

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

H. Akaza, Y. Tomita, S. Naito, 2014, Cancer science.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

The Therapeutic Effects of R 8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma

H. Nishiyama, H. Akaza, Takashi Nakamura, 2011 .

The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma.

H. Nishiyama, H. Akaza, Takashi Nakamura, 2011, Anticancer research.

Immunoprotection against murine bladder carcinoma by octaarginine‐modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette‐Guérin

H. Akaza, K. Kawai, J. Miyazaki, 2009, BJU international.

A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer

H. Akaza, S. Naito, K. Itoh, 2011, The Prostate.

histologic classification of renal cell carcinoma Clear cell renal cell carcinoma Multilocular clear cell renal cell carcinoma Papillary renal cell carcinoma Chromophobe renal cell carcinoma Carcinoma of the collecting ducts of Bellini Renal medullary carcinoma Xp 11 translocation carcinomas Carcino

H. Moch, V. Reuter, F. Algaba, 2011 .

Special Edition EAU-ICUD - Review - Kidney Cancer Current Pathology Keys of Renal Cell Carcinoma

H. Moch, V. Reuter, F. Algaba, 2011 .

Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro.

H. Akaza, V. Bilim, Y. Tomita, 2010, Anticancer research.

A bladder preservation regimen using intra‐arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective study

Y. Itai, Y. Akine, N. Miyanaga, 2000, International journal of urology : official journal of the Japanese Urological Association.

Detection and Cloning of a Protein Recognized by Anti‐human Prostate‐specific Antigen (PSA) Antibody in the Rat Ventral Prostate

T. Sugimura, Masahiko Watanabe, H. Akaza, 2001, Japanese journal of cancer research : Gann.

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.

A. Ravaud, R. Motzer, H. Akaza, 2010, American journal of respiratory and critical care medicine.

Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group.

H. Akaza, S. Naito, K. Imai, 1995, European urology.

Effects of single non-ortho, mono-ortho, and di-ortho chlorinated biphenyls on cell functions and proliferation of the human prostatic carcinoma cell line, LNCaP.

H. Akaza, W. Schill, T. Monsees, 2003, Reproductive toxicology.

A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome.

H. Akaza, K. Kawai, M. Minami, 2006, Japanese journal of clinical oncology.

ACaseofMetastaticTesticularCancerComplicatedbyTumourLysis Syndrome and Choriocarcinoma Syndrome

H. Akaza, K. Kawai, M. Minami, 2006 .

Urologic cancer in Japan: role of Japan at the frontier of issues in Asia.

H. Akaza, 2016, Japanese journal of clinical oncology.

Prediction of in vitro response to interferon‐α in renal cell carcinoma cell lines

H. Akaza, T. Kojima, J. Miyazaki, 2007 .

Dietary Isoﬂavones May Protect against Prostate Cancer in Japanese Men 1,2

N. Miyanaga, H. Akaza, S. Naito, 2007 .

Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer

H. Kume, H. Akaza, Y. Tomita, 2011, BJU international.

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

B. Rini, H. Akaza, M. Oya, 2016, Japanese journal of clinical oncology.

Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer

H. Akaza, K. Kawai, 2003, Expert opinion on drug safety.

Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis.

Yusuke Nakamura, T. Miki, H. Akaza, 2010, Japanese journal of clinical oncology.

AgNOR Count in Resting Cells (Resting NOR) Is a New Prognostic Marker in Invasive Bladder Tumor

H. Akaza, K. Uchida, T. Shimazui, 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.

H. Akaza, T. Takenaka, T. Takenaka, 1997, European urology.

Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system.

H. Akaza, K. Uchida, Y. Ono, 2000, Japanese journal of clinical oncology.

[Transabdominal ultrasonography for detection of urologic diseases in the general health check].

H. Akaza, N. Sekido, T. Shimazui, 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay

H. Akaza, K. Kawai, T. Ohno, 2005, Cancer Immunology, Immunotherapy.

Reiter’s syndrome following intravesical bacille biliÉ de Calmette–GuÉrin treatment for superficial bladder carcinoma: report of six cases

H. Akaza, Taichi Hayashi, I. Matsumoto, 2004, Modern rheumatology.

Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy:

T. Miki, N. Miyanaga, H. Akaza, 2007 .

Developing therapies for advanced bladder cancer

N. Miyanaga, H. Akaza, 2002, Expert opinion on investigational drugs.

Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system

H. Akaza, T. Niijima, K. Koiso, 1987, Cancer.

Serum creatinine and cholesterol levels of testicular cancer patients in long‐term follow up

N. Miyanaga, H. Akaza, K. Kawai, 2005, International journal of urology : official journal of the Japanese Urological Association.

Inverted papilloma: Observation with scanning and transmission electron microscopy

H. Akaza, T. Niijima, K. Kawabe, 2004, Virchows Archiv A.

Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers

T. Miki, H. Akaza, S. Kamidono, 2003, Cancer.

Type 1, P and S fimbriae, and afimbrial adhesin I are not essential for uropathogenic Escherichia coli to adhere to and invade bladder epithelial cells.

H. Akaza, J. Miyazaki, W. Ba-Thein, 2002, FEMS immunology and medical microbiology.

Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.

N. Miyanaga, H. Akaza, K. Kawai, 2006, Japanese journal of clinical oncology.

Identification of an Enzyme System for Daidzein-to-Equol Conversion in Slackia sp. Strain NATTS

H. Akaza, K. Nomoto, H. Tsuji, 2011, Applied and Environmental Microbiology.

Leuprorelin Acetate Depot: Results of a Multicentre Japanese Trial

H. Fuse, H. Akaza, T. Niijima, 1990, The Journal of international medical research.

Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men.

N. Miyanaga, H. Akaza, K. Kawai, 2008, The journal of sexual medicine.

Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine

H. Nishiyama, H. Akaza, K. Kawai, 2013, Cancer science.

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction.

P. Schellhammer, J. Witjes, K. Kurth, 1998, Urologic oncology.

New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells.

S. Futaki, H. Akaza, K. Kogure, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Preoperative Endocrine Therapy for Clinical Stage A2, B, and C Prostate Cancer: An Interim Report on Short‐Term Effects

Y. Homma, Y. Ohashi, H. Akaza, 1997, International journal of urology : official journal of the Japanese Urological Association.

Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation

Y. Homma, H. Akaza, Y. Hirao, 1999, International journal of urology : official journal of the Japanese Urological Association.

Maintenance intravesical bacillus Calmette‐Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group

H. Akaza, Y. Horiguchi, S. Naito, 2010, International journal of urology : official journal of the Japanese Urological Association.

Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids

H. Akaza, K. Saijo, K. Kawai, 2001, Cytotechnology.

Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette‐Guérin through Toll‐like receptor signalling

H. Akaza, K. Kawai, J. Miyazaki, 2006, BJU international.

Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan.

H. Akaza, M. Oya, O. Ogawa, 2014, Japanese journal of clinical oncology.

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients

H. Akaza, S. Naito, S. Pitman Lowenthal, 2015, Japanese journal of clinical oncology.

Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.

H. Akaza, K. Kawai, T. Shimazui, 2006, Japanese journal of clinical oncology.

High‐dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer

N. Miyanaga, H. Akaza, K. Kawai, 2000, International journal of urology : official journal of the Japanese Urological Association.

Neutropenic colitis as a complication of high-dose chemotherapy for refractory testicular cancer.

N. Miyanaga, H. Akaza, K. Kawai, 1998, Japanese journal of clinical oncology.

Novel nonsteroidal inhibitor of cytochrome P45017α (17α‐hydroxylase/C17–20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats

H. Akaza, T. Nakahara, H. Shikama, 1998, The Prostate.

Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.

N. Miyanaga, H. Akaza, T. Kojima, 2007, Japanese journal of clinical oncology.

Restoration of E-rosette formation by bestatin in patients with bladder cancer

H. Akaza, T. Niijima, H. Yokoyama, 2004, Journal of Cancer Research and Clinical Oncology.

Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer

T. Miki, H. Akaza, K. Ota, 2004, Cancer Chemotherapy and Pharmacology.

Acute Thrombosis in a Contralateral Kidney after Radical Nephrectomy: Successful Treatment by Thrombolytic Therapy Using a Tissue‐Type Plasminogen Activator

M. Tsutsumi, H. Akaza, T. Maruyama, 1996, International journal of urology : official journal of the Japanese Urological Association.

Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.

N. Miyanaga, H. Akaza, T. Kojima, 2004, Japanese journal of clinical oncology.

Asian trends in primary androgen depletion therapy on prostate cancer

H. Akaza, 2013, Cancer biology & medicine.

Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model

H. Nishiyama, H. Akaza, T. Kojima, 2019, PloS one.

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer

H. Akaza, K. Iizuka, I. Fukui, 2014, Cancer science.

Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database.

H. Akaza, M. Oya, O. Ogawa, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database.

H. Akaza, M. Oya, O. Ogawa, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic significance of nucleolar organizer region (AgNOR) in renal cell carcinoma.

H. Akaza, T. Shimazui, K. Hattori, 1995, The Journal of urology.

[A randomized trial of PVB, VAB-6, BVP regimen versus PEB chemotherapy in patients with disseminated testicular tumors].

H. Akaza, I. Fukui, K. Tobisu, 1991, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy.

S. Ishikawa, H. Akaza, S. Hinotsu, 1999, Japanese journal of clinical oncology.

Enhancement of T cell proliferative response against autologous cancer cells of a metasatic renal cell carcinoma patient after unexplained regression

H. Akaza, K. Saijo, K. Kawai, 2004, International journal of urology : official journal of the Japanese Urological Association.

Advances in chemotherapy of invasive bladder cancer

H. Akaza, 2000, Current opinion in urology.

Comparison of various assay systems for prostate-specific antigen standardization.

H. Akaza, Y. Kawada, S. Akimoto, 1992, Japanese journal of clinical oncology.

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events.

D. Lamm, J. Witjes, M. Colombel, 2008 .

Unusual presentation of necrotizing fasciitis in a patient who had achieved long‐term remission after irradiation for testicular cancer

T. Miyagawa, H. Akaza, K. Kawai, 2005, International journal of urology : official journal of the Japanese Urological Association.

Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.

N. Miyanaga, H. Akaza, Y. Hasegawa, 2006, Japanese journal of clinical oncology.

The effect of dose intensity on M-VAC therapy for advanced urothelial cancer

N. Miyanaga, H. Akaza, T. Shimazui, 2004, Cancer Chemotherapy and Pharmacology.

Recent Trends in Hormone Therapy for Prostate Cancer in Japan

H. Akaza, M. Onozawa, 2018 .

[Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy].

H. Akaza, T. Niijima, K. Kawabe, 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.

H. Akaza, Naoko Ushida, Ryohei Kurihara, 2019, Japanese journal of clinical oncology.

[Experimental intravesical treatment of bladder tumor with Concanavalin-A conjugated bleomycin].

H. Akaza, M. Soloway, T. Niijima, 1984, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Telomerase Is Upregulated in Irreversible Preneoplastic Lesions during Bladder Carcinogenesis in Rats

N. Miyanaga, H. Akaza, T. Shimazui, 2002, Japanese journal of cancer research : Gann.

Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.

T. Hashimoto, K. Kagei, Y. Akine, 2006, International journal of radiation oncology, biology, physics.

[Assessment of QOL and survival for patients undergoing radical cystectomy or bladder preservation for invasive bladder cancer].

N. Miyanaga, H. Akaza, N. Shinohara, 1999, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.

H. Nishiyama, H. Akaza, S. Naito, 2013, Japanese journal of clinical oncology.

Objective response criteria in phase II and phase III studies.

H. Akaza, A. van Oosterom, W. Jones, 1988, Progress in clinical and biological research.

前立腺癌患者の身体・精神・社会面に対する病名告知の影響

S. Ishikawa, H. Akaza, Hideto Takahashi, 1997 .

Intraoperative transesophageal echocardiography for inferior vena caval tumor thrombus in renal cell carcinoma

N. Miyanaga, H. Akaza, K. Kawai, 2004, International journal of urology : official journal of the Japanese Urological Association.

Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma.

S. Saga, H. Akaza, K. Kawai, 2003, International journal of oncology.

Subsets of T lymphocytes of patients with malignancies of the urogenital tract.

H. Akaza, T. Niijima, H. Yokoyama, 1979, Cellular and molecular biology, including cyto-enzymology.

Clinical Practice Manual for Late‐onset Hypogonadism Syndrome

H. Akaza, T. Yanase, Hiroaki Kumano, 2008, International journal of urology : official journal of the Japanese Urological Association.

Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes

M. Noguchi, H. Akaza, K. Saijo, 2003, Clinical and experimental immunology.

Bladder cancer: Advancing NMIBC treatment beyond current BCG formulations

H. Akaza, 2016, Nature Reviews Urology.

Antineoplastic activity of honey in an experimental bladder cancer implantation model: In vivo and in vitro studies

N. Miyanaga, H. Akaza, K. Kawai, 2003, International journal of urology : official journal of the Japanese Urological Association.

Habitual Intake of Lactic Acid Bacteria and Risk Reduction of Bladder Cancer

Y. Ohashi, N. Miyanaga, H. Akaza, 2002, Urologia Internationalis.

Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2.

H. Akaza, A. Kushiro, K. Nomoto, 2001, The Journal of urology.

New treatment approaches for superficial and invasive bladder cancer.

H. Grossman, H. Akaza, F. Debruyne, 1998, Urologic oncology.

[Influence of Lactobacillus casei on rat bladder carcinogenesis].

Y. Homma, H. Akaza, K. Nomoto, 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice].

N. Miyanaga, H. Akaza, T. Kakizoe, 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Chemoimmunotherapy of implanted murine bladder cancer.

H. Akaza, M. Soloway, W. Crabtree, 1983, Urology.

Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor.

H. Akaza, S. Hinotsu, T. Shimazui, 2000, The Journal of urology.

[The squash technique for silver staining of argyrophilic nucleolar organizer regions on bladder tumors: comparison with paraffin embedded sections].

H. Akaza, T. Shimazui, K. Hattori, 1995, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Evaluation of Nucleolar Organizer Regions in Human Bladder Cancers by Light- and Electron-Microscopic Morphometry

H. Akaza, Y. Uchiyama, K. Uchida, 1998, European Urology.

Diagnosis of Non-Muscle Invasive Bladder Cancer

D. Lamm, J. Witjes, M. Colombel, 2008 .

[Histological and flow cytometric analyses of carcinogenesis of rat prostate cancer].

H. Akaza, T. Shirai, Y. Aso, 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer.

K Koiso, S. Ishikawa, N. Miyanaga, 1997, European urology.

Case of α‐fetoprotein‐producing transitional cell carcinoma of the renal pelvis

M. Noguchi, T. Iijima, H. Akaza, 2004 .

Case of alpha-fetoprotein-producing transitional cell carcinoma of the renal pelvis.

M. Noguchi, T. Iijima, H. Akaza, 2004, International journal of urology : official journal of the Japanese Urological Association.

[Significance of tumor markers in the treatment of urological malignancies].

H. Akaza, S. Kameyama, Y. Aso, 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

Clinical study of varicocele: Statistical analysis and the results of long‐term follow‐up

H. Akaza, M. Onozawa, F. Endo, 2002, International journal of urology : official journal of the Japanese Urological Association.

Protecting spermatogonia from apoptosis induced by doxorubicin using the luteinizing hormone‐releasing hormone analog leuprorelin

H. Akaza, F. Endo, H. Takeshima, 2003, International journal of urology : official journal of the Japanese Urological Association.

[The relationship between the estimated tumor growth speed and indices of bromodeoxyuridine (BrdU) incorporation and the proliferating cell nuclear antigen (PCNA) expression in superficial bladder cancer].

H. Akaza, T. Ota, K. Hattori, 1997, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Surface markers of lymphocytes infiltrating seminoma tissue.

H. Akaza, T. Niijima, K. Kobayashi, 1980, The Journal of urology.

Non Muscle Invasive Bladder Cancer Cases Initially Failing to Respond to Bacillus Calmette-Guérin Intravesical Instillation Therapy

H. Akaza, K. Tozawa, K. Kohri, 2010, Current Urology.

[Effects of LH-RH analogue on pituitary-testicular axis and bladder carcinogenesis of BBN administered male rats].

H. Akaza, S. Kameyama, Y. Aso, 1989, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer

T. Miki, H. Akaza, Y. Kubota, 1999, International journal of urology : official journal of the Japanese Urological Association.

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

H. Akaza, S. Naito, H. Fujimoto, 2010, Cancer Chemotherapy and Pharmacology.

Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection

Y. Ohashi, H. Akaza, S. Hinotsu, 1999, Cancer.

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

M. Cooperberg, P. Carroll, J. Broering, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.

Yair Lotan, Serge Benayoun, Pierre I Karakiewicz, 2005, The Journal of urology.

Acute multifocal bacterial nephritis complicated with acute renal failure and thrombocytopenia.

H. Akaza, K. Yamagata, A. Koyama, 2005, Internal medicine.

M. Noguchi, J. Kano, H. Akaza, 2011, Cancer science.

A case of metastatic testicular cancer complicated by pulmonary hemorrhage due to choriocarcinoma syndrome

N. Miyanaga, H. Akaza, K. Kawai, 2010, International Journal of Clinical Oncology.

Hamartoma of the urinary bladder

H. Akaza, K. Kawai, M. Harada, 1999, International journal of urology : official journal of the Japanese Urological Association.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

I. Tannock, M. Rubin, A. Chinnaiyan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management

M. Cooperberg, P. Carroll, H. Akaza, 2014, Prostate international.

The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer.

N. Miyanaga, H. Akaza, K. Kawai, 2003, Japanese journal of clinical oncology.

The level of cadherin‐6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma

S. Saga, H. Akaza, K. Yoshikawa, 2004, Cancer.

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer : Comparison of Current Guidelines and Recommendations

D. Lamm, J. Witjes, M. Colombel, 2008 .

Long-term clinical study on Luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer

H. Akaza, T. Niijima, Y. Aso, 1992 .

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

Y. Lotan, A. Sagalowsky, S. Shariat, 2008, BJU international.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma

H. Akaza, R. Horie, T. Kojima, 2010, Genes, chromosomes & cancer.

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance

A. Gemma, H. Akaza, I. Hyodo, 2015, Japanese journal of clinical oncology.

Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors.

J. Schalken, H. Akaza, F. Debruyne, 1996, Cancer research.

Alterations in Expression of Cadherin–6 and E–Cadherin during Kidney Development and in Renal Cell Carcinoma

J. Schalken, H. Akaza, F. Debruyne, 2000, European Urology.

Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up study

N. Miyanaga, H. Akaza, K. Kawai, 2010, International journal of urology : official journal of the Japanese Urological Association.

Low expression of microphthalmia‐associated transcription factor, a potential molecular target for interferon‐alpha susceptibility, is associated with metastasis in renal cell carcinoma

H. Akaza, T. Kojima, K. Yoshikawa, 2009, Cancer science.

Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

D. Murphy, H. Akaza, I. Davis, 2018, BJU international.

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching

H. Akaza, M. Oya, O. Ogawa, 2018, Cancer medicine.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019 .

Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.

H. Akaza, S. Naito, T. Tsukamoto, 2008, Japanese journal of clinical oncology.

Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

H. Akaza, O. Ogawa, M. Murai, 2007, Japanese journal of clinical oncology.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.

M. Noguchi, H. Akaza, R. Mulligan, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Advanced renal cell carcinoma treated with granulocyte‐macrophage colony‐stimulating factor gene therapy: A clinical course of the first Japanese experience

M. Noguchi, H. Akaza, R. Mulligan, 2002, International journal of urology : official journal of the Japanese Urological Association.

Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines.

H. Akaza, S. Asano, K. Kawai, 2000, Molecular urology.

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)

H. Akaza, H. Uemura, H. Uemura, 2014, Japanese journal of clinical oncology.

NCCN Asia Consensus Statement prostate cancer.

H. Akaza, M. Namiki, S. Hinotsu, 2018, Japanese journal of clinical oncology.

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

H. Akaza, 2010, Pharmacology.

Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.

H. Akaza, T. Fukagai, Y. Kitagawa, 2012, Asian journal of andrology.

Evidence‐based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition)

H. Akaza, S. Kamidono, S. Egawa, 2008, International journal of urology : official journal of the Japanese Urological Association.

Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

H. Akaza, R. Umbas, E. Chiong, 2012, The Lancet. Oncology.

The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Y. Ohashi, H. Akaza, S. Naito, 2012, Japanese journal of clinical oncology.

Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management.

M. Cooperberg, P. Carroll, H. Akaza, 2012, Japanese journal of clinical oncology.

[Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].

H. Akaza, S. Kagawa, J. Shimazaki, 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

Injection of Glutaraldehyde Cross‐Linked Collagen for Urinary Incontinence: Two‐Year Efficacy by Self‐Assessment

H. Akaza, E. Yokoyama, K. Koshiba, 1996, International journal of urology : official journal of the Japanese Urological Association.

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.

T. Matsuda, Y. Ohashi, H. Akaza, 2004, Japanese journal of clinical oncology.

Successful management by provocative angiography and endovascular stent of Ureteroarterial fistula in a patient with a long-term indwelling ureteral stent.

H. Akaza, M. Minami, N. Sekido, 2010, Japanese journal of clinical oncology.

Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling

Hiromu Suzuki, H. Akaza, T. Michiue, 2009, Oncogene.

How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study?

H. Akaza, K. Kawai, N. Sekido, 2006, International journal of urology : official journal of the Japanese Urological Association.

Pharmacokinetics of Tamsulosin Hydrochloride in Patients with Renal Impairment: Effects of α1‐Acid Glycoprotein

H. Akaza, S. Higuchi, H. Kamimura, 1996, Journal of clinical pharmacology.

Primary signet ring cell carcinoma of the bladder effectively treated with intra-arterial chemotherapy and radiation therapy: A case report

H. Akaza, S. Hinotsu, T. Shimazui, 1995 .

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study

A. Gemma, N. Saijo, N. Miyanaga, 2020, Japanese journal of clinical oncology.

Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma.

J. Schalken, A. van Bokhoven, H. Akaza, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor–specific autologous cytotoxic T lymphocytes from tissue sections

H. Akaza, K. Saijo, K. Kawai, 1996, Nature Medicine.

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)

F. Saad, J. Nelson, H. Scher, 2014 .

Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting

M. Cooperberg, P. Carroll, S. Mun, 2017, Prostate international.

THE SIGNIFICANCE OF LYMPHOCYTIC INFILTRATION IN UROLOGIC TUMORS: STUDIES OF DISTRIBUTIONS OF B AND T-LYMPHO- CYTES AND ITS SUBSETS, AND FUNCTIONAL ANALYSIS OF THE INFILTRATING LYMPHOCYTES

H. Akaza, 2010 .

Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association

Y. Mizutani, T. Miki, H. Akaza, 2009, International journal of urology : official journal of the Japanese Urological Association.

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

H. Akaza, Y. Tomita, S. Naito, 2013, Japanese journal of clinical oncology.

Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi‐institutional Japan‐wide database

H. Kume, H. Akaza, M. Shiota, 2021, International journal of urology : official journal of the Japanese Urological Association.

Trans‐Pacific variation in outcomes for men treated with primary androgen‐deprivation therapy (ADT) for prostate cancer

M. Cooperberg, P. Carroll, H. Akaza, 2016, BJU international.

Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case–control study among Japanese men

H. Akaza, N. Masumori, T. Miura, 2016, International Urology and Nephrology.

Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP.

T. Sugimura, H. Akaza, K. Wakabayashi, 1998, Japanese journal of clinical oncology.

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Raj Persad, J Alfred Witjes, Andreas Böhle, 2011, The Journal of urology.

Bropirimine, an Orally Active Anticancer Agent for Superficial Bladder Cancer

H. Akaza, T. Machida, T. Kotake, 1998, European Urology.

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer

D. Lamm, J. Witjes, M. Colombel, 2008 .

Bladder cancer induced by noncarcinogenic substances.

H. Akaza, M. Soloway, W. Murphy, 1984, The Journal of urology.

Increase of T lymphocytes bearing immunoglobulin G receptors during circulation in human renal cell carcinoma.

H. Akaza, T. Niijima, K. Kobayashi, 1982, The Journal of urology.

Treated natural history of superficial bladder cancer.

Y. Ohashi, S. Fukushima, H. Akaza, 2001, Japanese journal of clinical oncology.

Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer research group for Adriamycin

Y. Ohashi, H. Akaza, T. Machida, 2004, Cancer Chemotherapy and Pharmacology.

Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer

H. Akaza, T. Niijima, K. Koiso, 2004, Cancer Chemotherapy and Pharmacology.

Low-grade Ta (noninvasive) urothelial carcinoma of the bladder.

C. Busch, P. Sved, H. Akaza, 2005, Urology.

[Urethral occurrence of bladder cancer following cystectomy].

H. Akaza, T. Niijima, K. Kawabe, 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.

H. Akaza, T. Nakahara, H. Shikama, 1999, Japanese journal of pharmacology.

A NEW TUMOR MARKER FOR BLADDER CANCER

N. Miyanaga, H. Akaza, K. Koiso, 1994, International journal of urology : official journal of the Japanese Urological Association.

Induction of potent antitumour natural‐killer cells from peripheral blood of patients with advanced prostate cancer

H. Akaza, K. Kawai, I. Ishiwata, 2003, BJU international.

The liposome‐incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette‐Guéin can directly enhance the susceptibility of cancer cells to lymphokine‐activated killer cells through up‐regulation of natural‐killer group 2, member D ligands

H. Akaza, Takashi Nakamura, T. Kojima, 2011, BJU international.

Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.

H. Akaza, T. Shinka, S. Naito, 2006, Urology.

A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder.

H. Akaza, T. Kakizoe, K. Kawabe, 2003, Japanese journal of clinical oncology.

Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results

H. Akaza, T. Kakizoe, S. Hinotsu, 1995 .

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group.

H. Akaza, T. Kakizoe, S. Hinotsu, 1995, Cancer.

BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder.

H. Akaza, 1995, European urology.

Long‐term results of first‐line sequential high‐dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor

Y. Mizutani, T. Miki, H. Akaza, 2007, International journal of urology : official journal of the Japanese Urological Association.

Pheochromocytoma with remission following phentolamine-induced shock.

H. Akaza, T. Niijima, K. Kawabe, 1984, Urology.

Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.

H. Akaza, K. Itoh, Masayuki Yamamoto, 2007, Carcinogenesis.

Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice.

Y. Fujii‐Kuriyama, H. Akaza, K. Itoh, 2010, Journal of biochemistry.

Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells.

H. Akaza, T. Niijima, S. Iwasa, 1987, Chemical & pharmaceutical bulletin.

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder

A. Sagalowsky, H. Huland, S. Shariat, 2006, BJU international.

Prognostic Value of Cadherin-associated Molecules (a-, /3-, and y-Catenins and pl20cfli) in Bladder Tumors

J. Schalken, H. Akaza, C. Jansen, 2017 .

Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men

Hiromu Suzuki, N. Miyanaga, H. Akaza, 2010, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients Receiving Chemotherapy for Urogenital Cancer

H. Akaza, Y. Aso, 1992 .

[Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: pilot study].

D. Cella, N. Miyanaga, H. Akaza, 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

H. Yaegashi, H. Akaza, K. Nakashima, 2013, International journal of urology : official journal of the Japanese Urological Association.

Association of HER‐2 polymorphism with Japanese sporadic prostate cancer susceptibility

N. Kinukawa, H. Akaza, A. Yokomizo, 2005, The Prostate.

Prostate Cancer Chemoprevention Study: An investigative randomized control study using purified isoflavones in men with rising prostate‐specific antigen

N. Miyanaga, H. Akaza, T. Fujioka, 2012, Cancer science.

Enzyme activity and protein content of superoxide dismutase isozymes in human renal cell carcinoma.

H. Akaza, K. Kawai, Y. Kumagai, 2000, Research Communications in Molecular Pathology and Pharmacology.

Clinical evaluation of urethral tumors based on a simple classification system.

Y. Homma, H. Akaza, K. Matsumoto, 1988, European Urology.

What is the Asian Consensus Statement on NCCN clinical practice guidelines in oncology (NCCN-ACS)?

H. Akaza, 2016, Japanese journal of clinical oncology.

792PTREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA.

S. Hitier, H. Akaza, G. Fountzilas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A case of intravascular papillary endothelial hyperplasia (Masson's tumor) arising from renal sinus.

M. Noguchi, N. Miyanaga, H. Akaza, 1997, Japanese journal of clinical oncology.

Cavernous hemangioma mimicking a cystic renal cell carcinoma

H. Akaza, K. Kawai, N. Sekido, 2008, International Journal of Clinical Oncology.

Epidemiological Survey of Sexually Transmitted Diseases Prevalence in Japan : Sentinel Surveillance of STDs in 2000

H. Akaza, S. Kamidono, S. Kagawa, 2001 .

The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.

H. Akaza, Wun-Jae Kim, Choung-Soo Kim, 2007, Asian Pacific journal of cancer prevention : APJCP.

The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.

H. Akaza, T. Fujioka, Wun-Jae Kim, 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010

H. Yasunaga, H. Akaza, K. Okihara, 2010, International journal of urology : official journal of the Japanese Urological Association.

Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.

F. Saad, B. Tombal, H. Akaza, 2021 .

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

H. Akaza, Y. Enomoto, Kazuhiro Suzuki, 2019, Cancer medicine.

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

Y. Ohashi, H. Akaza, S. Horie, 2018, Cancer science.

Title Fifth joint meeting of J-CaP and CaPSURE : Advancing the global understanding of prostate cancer and its management Permalink

M. Cooperberg, P. Carroll, H. Akaza, 2012 .

Long-term survival of extremely advanced prostate cancer patients diagnosed with prostate-specific antigen over 500 ng/ml.

H. Yasunaga, T. Sugihara, M. Kattan, 2014, Japanese journal of clinical oncology.

Roundtable discussion at the UICC World Cancer Congress: looking toward the realization of universal health coverage for cancer in Asia.

E. Trimble, H. Akaza, J. Roh, 2015, Asian Pacific journal of cancer prevention : APJCP.

Response criteria phase II/phase III invasive bladder cancer.

I. Tannock, H. Akaza, D. Raghavan, 1986, Progress in clinical and biological research.

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan

H. Akaza, S. Holmstrom, S. Inoue, 2021, Japanese journal of clinical oncology.

Expression of antitumor response role of attachment and viability of bacillus calmette—guérin to bladder cancer cells

H. Akaza, N. Ikeda, K. Koiso, 1993, Cancer.

Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.

H. Akaza, T. Niijima, S. Hinotsu, 2004, European urology.

Addition of bicalutamide 80 mg to LHRH-agonist monotherapy in patients with advanced prostate cancer: Impact on quality of life.

T. Deguchi, Y. Ohashi, H. Akaza, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

H. Kume, H. Akaza, M. Shiota, 2021, Cancer science.

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

H. Akaza, M. Murai, S. Naito, 2007, Japanese journal of clinical oncology.

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

N. Miyanaga, H. Akaza, T. Yamanouchi, 2011, Japanese journal of clinical oncology.

Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection

S. Ishikawa, N. Miyanaga, H. Akaza, 2003, International Journal of Clinical Oncology.

Lower Urinary Tract Dysfunction as Persistent Complication of Radical Hysterectomy

H. Akaza, K. Kawai, N. Sekido, 1997, International journal of urology : official journal of the Japanese Urological Association.

Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.

T. Miki, H. Akaza, B. Houk, 2010, Japanese journal of clinical oncology.

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

T. Miki, H. Akaza, B. Houk, 2010, Japanese journal of clinical oncology.

Prostate cancer chemoprevention by soy isoflavones: Role of intestinal bacteria as the “second human genome”

H. Akaza, 2012, Cancer science.

A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: a multicenter open study

T. Miki, H. Akaza, S. Naito, 2006, International Journal of Clinical Oncology.

Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.

Y. Homma, Y. Ohashi, H. Akaza, 2000, Japanese journal of clinical oncology.

Review article Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction

H. Akaza, K. Naito, Richard D. Williams, 1999 .

[Nondestructive synchrotron radiation X-ray fluorescence imaging of trace elements in renal cell carcinoma].

H. Akaza, R. Nemoto, K. Koiso, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

A case‐control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet

N. Miyanaga, H. Akaza, T. Fujioka, 2004, Cancer science.

Report of the third Asian Prostate Cancer study meeting

M. Cooperberg, D. Murphy, H. Akaza, 2018, Prostate international.

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study

H. Akaza, M. Oya, S. Horie, 2021, BJUI Compass.

New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence.

H. Akaza, 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

Comparative investigation on use of (2''R)-4'-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors.

H. Akaza, T. Niijima, T. Hisamatsu, 1988, Urology.

[Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].

Y. Ohashi, H. Akaza, T. Machida, 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer

H. Akaza, T. Machida, T. Niijima, 1987, Cancer Chemotherapy and Pharmacology.

Stimulatory effects of growth hormone on rat bladder carcinogenesis

H. Akaza, Y. Aso, K. Koiso, 1991, Cancer.

Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five‐year results

Y. Homma, Y. Ohashi, H. Akaza, 2004, International journal of urology : official journal of the Japanese Urological Association.

Bladder-preserving therapy for muscle-invasive bladder cancer: Should it be recommended to appropriate patients?

H. Akaza, 2008, Current urology reports.

Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy.

N. Miyanaga, H. Akaza, K. Kawai, 2007, Japanese journal of clinical oncology.

[Multidisciplinary treatment of invasive bladder cancer].

H. Akaza, T. Niijima, K. Isurugi, 1986, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.

H. Akaza, K. Kawai, J. Miyazaki, 2003, Japanese journal of clinical oncology.

Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan.

N. Miyanaga, H. Akaza, N. Masumori, 2011, Asian Pacific journal of cancer prevention : APJCP.

Prophylactic chemotherapy with intravesical instillation of Adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer

Y. Ohashi, H. Akaza, S. Kagawa, 2004, Cancer Chemotherapy and Pharmacology.

The 4th study of prophylactic intravesical chemotherapy with Adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group of Adriamycin

Y. Ohashi, H. Akaza, T. Machida, 2004, Cancer Chemotherapy and Pharmacology.

Mutual neoplastic promotion by instillation of mitomycin C and cauterization on rat bladder urothelium

H. Akaza, T. Niijima, K. Koseki, 1986, Cancer.

Prophylactic Intravesical Chemotherapy: Its Unexpected Course

H. Akaza, T. Niijima, Shohei Nakamura, 1982 .

[The role of mechanical stimuli in rat bladder carcinogenesis. Regenerative hyperplasia of rat urinary bladder urothelium after transurethral fulguration].

H. Akaza, T. Niijima, N. Moriyama, 1984, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.

D. Lamm, M. Colombel, H. Akaza, 2010, European urology.

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

H. Akaza, Y. Shibasaki, Y. Umeyama, 2017, Future oncology.

[Clinical study of RU 23908 (nilutamide) in prostatic cancer].

H. Fuse, H. Akaza, H. Yamanaka, 1991, Hinyokika kiyo. Acta urologica Japonica.

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial

H. Akaza, M. Oyama, G. Kimura, 2017, Japanese Journal of Clinical Oncology.

Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.

H. Nishiyama, N. Miyanaga, H. Akaza, 2012, Japanese journal of clinical oncology.

Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis

J. Sakamoto, H. Akaza, T. Taguchi, 2006, Journal of Cancer Research and Clinical Oncology.

Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257))

I. Tannock, M. Rubin, A. Chinnaiyan, 2019 .

Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer

Y. Homma, Y. Ohashi, H. Akaza, 2004, International journal of urology : official journal of the Japanese Urological Association.

Splenogonadal fusion: Case report and review of published works

H. Akaza, T. Shimazui, K. Hattori, 2006, International journal of urology : official journal of the Japanese Urological Association.

Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort

H. Akaza, M. Oya, O. Ogawa, 2014, Journal of Cancer Research and Clinical Oncology.

The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).

H. Akaza, Seiichiro Yamamoto, N. Ishizuka, 2002, Japanese journal of clinical oncology.

Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan

H. Akaza, M. Oya, K. Tatsugami, 2020, Expert review of anticancer therapy.

Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.

H. Akaza, M. Oya, K. Tatsugami, 2016, Gan to kagaku ryoho. Cancer & chemotherapy.

Should patients with localized prostate cancer receive primary androgen deprivation therapy?

H. Akaza, A. Mizokami, M. Namiki, 2008, Nature Clinical Practice Urology.

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

H. Akaza, M. Oya, K. Tatsugami, 2018, British Journal of Cancer.

Phase III trial of The Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder

H. Akaza, T. Machida, T. Niijima, 2004, Cancer Chemotherapy and Pharmacology.

Bladder reconstruction using a collagen patch prefabricated within the omentum

T. Miyagawa, H. Akaza, K. Kawai, 2006, International journal of urology : official journal of the Japanese Urological Association.

[Phenotypic difference of lymphocytes circulating in tumorous renal artery and renal vein in patients with renal cell carcinoma].

N. Miyanaga, H. Akaza, K. Kawai, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[Clinical statistical studies of bladder cancer in Japan].

N. Miyanaga, H. Akaza, K. Koiso, 1993, Nihon rinsho. Japanese journal of clinical medicine.

Laminin expression patterns in human ureteral tissue.

K. Sekiguchi, H. Akaza, K. Kawai, 2003, The Journal of urology.

A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, H. Akaza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aim of the working group on the Asian perspectives on cancer control: Asian perspective on prostate cancer prevention.

H. Akaza, 2010, Japanese journal of clinical oncology.

Evaluation of the effectiveness of sildenafil using questionnaire methods versus audio‐visual sexual stimulation

H. Akaza, F. Endo, T. Suetomi, 2005, International journal of urology : official journal of the Japanese Urological Association.

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

Y. Ohashi, H. Akaza, S. Naito, 2017, Japanese journal of clinical oncology.

[Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].

H. Akaza, S. Naito, T. Taguchi, 2001, Hinyokika kiyo. Acta urologica Japonica.

Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma.

J. Schalken, H. Akaza, F. Debruyne, 1998, International Journal of Cancer.

Surviving cancer in Asia: cross-boundary cancer studies, University of Tokyo.

H. Akaza, 2021, Japanese journal of clinical oncology.

UICC International Session: What are the implications of sharing the concept of Universal Health Coverage for cancer in Asia?

H. Akaza, J. Roh, E. Park, 2016, Cancer science.

Japanese Cancer Association Meeting UICC International session--what is cost-effectiveness in cancer treatment?

H. Akaza, J. Roh, E. Park, 2014, Asian Pacific journal of cancer prevention : APJCP.

Challenges and outlook for the UICC-Asian Regional Office.

H. Akaza, 2013, Asian Pacific journal of cancer prevention : APJCP.

[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].

H. Akaza, T. Funyu, M. Togashi, 1992, Hinyokika kiyo. Acta urologica Japonica.

[Adult Wilms's tumor with histologically dissisimilar lung metastasis].

N. Miyanaga, H. Akaza, T. Yazawa, 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.

H. Akaza, Y. Tomita, M. Fujisawa, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Global update on defining and treating high‐risk localized prostate cancer with leuprorelin: a Japanese perspective – the effect of primary androgen deprivation therapy on stage C prostate cancer

H. Akaza, 2007, BJU international.

[Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group].

H. Akaza, H. Kojima, T. Kakizoe, 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Principle Component Analysis of Health-Related Quality of Life Measures for Prostate Cancer

H. Akaza, S. Horie, M. Kanayama, 2016 .

雄性ラットのN-butyl-N-(4-hydroxybutyl) nitrosamine 膀胱発癌に及ぼす Luteinizing hormone-releasing hormone agonist の影響

H. Akaza, Y. Aso, K. Matsuki, 1992 .

[Effects of luteinizing hormone-releasing hormone agonist on bladder carcinogenesis in male rats].

H. Akaza, Y. Aso, K. Matsuki, 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer

N. Kinukawa, H. Akaza, A. Yokomizo, 2004, The Prostate.

Symposium: “Oncology Leadership in Asia”

Kazuhiro Yoshida, D. Noh, Z. Aziz, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[Cases of refractory testicular cancer treated with all trans-retinoic acid].

N. Miyanaga, H. Akaza, K. Kawai, 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

[Discriminant analysis of quantification theory on prognostic factors of chemotherapeutic effects on advanced testicular cancer. East Japan Testicular Tumor Study Group].

H. Akaza, I. Fukui, K. Tobisu, 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.

H. Akaza, Y. Sawamura, M. Otani, 1988, Japanese journal of clinical oncology.

H. Akaza, H. Kanetake, S. Isaka, 1996, International journal of urology : official journal of the Japanese Urological Association.

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

T. Miki, H. Akaza, O. Ogawa, 2013, International Journal of Clinical Oncology.

Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study

H. Akaza, Jasmine Lim, W. J. Koh, 2021, Cancer medicine.

Strategy for Prevention of Recurrence of Superficial Bladder Cancer

H. Akaza, 1996 .

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

H. Akaza, S. Naito, Se-Hoon Lee, 2012, Japanese journal of clinical oncology.

Genetic heterogeneity of surgically resected prostate carcinomas and their biopsy specimens is related to their histologic differentiation

M. Noguchi, H. Akaza, T. Shimazui, 2001, Cancer.

[A case of urinary ascites probably caused by spontaneous bladder rupture].

H. Akaza, K. Kawai, N. Sekido, 1995, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[A case of papillary cystadenoma of the epididymis].

H. Akaza, K. Oka, A. Araki, 1998, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Transurethral resection of benign prostatic hyperplasia using a vaporizing resecting loop, UROloop.

N. Miyanaga, H. Akaza, K. Kawai, 1999, Hinyokika kiyo. Acta urologica Japonica.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Progress in prostate cancer chemoprevention: modulators of promotion and progression.

I. Thompson, W. Fair, H. Akaza, 2001, Urology.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.

Yusuke Nakamura, T. Miki, H. Akaza, 2011, Japanese journal of clinical oncology.

The 2nd conference on Asian trends in prostate cancer hormone therapy.

H. Akaza, T. Fujioka, Wun-Jae Kim, 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

MP-16.14 Improved Grouping System Combining Gleason Score for Group IV of TNM Prognostic Grouping for Prostate Cancer: Results from J-CAP Database

H. Akaza, O. Ogawa, M. Murai, 2011 .

[Detection of numerical chromosome aberrations in urologic malignancies using in situ hybridization from formarin-fixed paraffin sections].

F. Mostofi, I. Sesterhenn, H. Akaza, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)

H. Akaza, S. Naito, N. Shinohara, 2008 .

Immunological protection induced by bacillus Calmette–Guérin treatment in a murine bladder tumor model

H. Akaza, K. Kawai, N. Ikeda, 2002, International journal of urology : official journal of the Japanese Urological Association.

Proven Efficacy of Combined Androgen Depletion Therapy

H. Akaza, 2010, Current urology reports.

[Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer].

S. Nishimura, H. Akaza, S. Naito, 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels

H. Akaza, A. Shinbo, K. Gotanda, 2003, Prostate Cancer and Prostatic Diseases.

[Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].

H. Akaza, T. Niijima, M. Matsuda, 1988, Hinyokika kiyo. Acta urologica Japonica.

[Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].

H. Akaza, T. Niijima, M. Matsuda, 1988, Hinyokika kiyo. Acta urologica Japonica.

Retroperitoneal extragonadal germ cell tumor in a patient with Klinefelter's syndrome

M. Noguchi, Y. Morishita, H. Akaza, 2005, International journal of urology.

[Effects of UFT in advanced renal cell cancer].

H. Akaza, T. Niijima, K. Isurugi, 1985, Gan to kagaku ryoho. Cancer & chemotherapy.

[A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9].

H. Akaza, A. Yamauchi, T. Shimazui, 2001, Hinyokika kiyo. Acta urologica Japonica.

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

H. Akaza, M. Oya, K. Tatsugami, 2018, British Journal of Cancer.

Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma

H. Akaza, S. Naito, K. Kawai, 2013, International Journal of Clinical Oncology.

The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study

H. Akaza, K. Kawakami, T. Oikawa, 2012, Supportive Care in Cancer.

Prospective study of combined treatment with interferon‐alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma

Y. Mizutani, T. Miki, H. Akaza, 2008, International journal of urology : official journal of the Japanese Urological Association.

Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer

Y. Ohashi, H. Akaza, T. Machida, 2004, Cancer Chemotherapy and Pharmacology.

[Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].

N. Miyanaga, H. Akaza, M. Hosaka, 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].

H. Akaza, A. Maru, T. Niijima, 1986, Hinyokika kiyo. Acta urologica Japonica.

[Experiences of total cystectomy for superficial bladder cancer].

H. Akaza, T. Niijima, K. Kawabe, 1984, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

H. Akaza, M. Murai, S. Naito, 2011, BJU international.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines.

J. Schalken, H. Akaza, E. Oosterwijk, 2004, Oncology reports.

The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Y. Ohashi, H. Akaza, S. Naito, 2012, Japanese Journal of Clinical Oncology.

Prostate Cancer Chemoprevention Study: An investigative randomized control study using purified isoflavones in men with rising prostate‐specific antigen

N. Miyanaga, H. Akaza, T. Fujioka, 2012, Cancer science.

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

N. Miyanaga, H. Akaza, T. Yamanouchi, 2011, Japanese journal of clinical oncology.

Aim of the working group on the Asian perspectives on cancer control: Asian perspective on prostate cancer prevention.

H. Akaza, 2010, Japanese journal of clinical oncology.

President ’ s Statement Aim of the Working Group on the Asian Perspectives on Cancer Control : Asian Perspective on Prostate Cancer Prevention

H. Akaza, 2010 .

Trans‐Pacific variation in outcomes for men treated with primary androgen‐deprivation therapy (ADT) for prostate cancer

M. Cooperberg, P. Carroll, H. Akaza, 2016, BJU international.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

I. Tannock, M. Rubin, A. Chinnaiyan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan

H. Akaza, Kazuhiro Suzuki, M. Namiki, 2015, Japanese journal of clinical oncology.

Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?

H. Akaza, 2005, The Canadian journal of urology.

Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan

H. Nishiyama, H. Akaza, M. Oya, 2018, International Journal of Clinical Oncology.

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

Y. Lotan, A. Sagalowsky, S. Shariat, 2008, BJU international.

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

D. Lamm, J. Witjes, M. Colombel, 2011, The Journal of urology.

Significance of the BTA Test in Bladder Cancer: A Multicenter Trial

N. Miyanaga, H. Akaza, S. Ozono, 1997, International journal of urology : official journal of the Japanese Urological Association.

Epidemiology and prevention

H. Akaza, 2016 .

Renal oncocytoma mimicking hemorrhagic renal cyst.

H. Akaza, K. Kawai, N. Sekido, 1995, International journal of urology.

Species differences in regenerative hyperplasia of bladder urothelium after transurethral cauterization

H. Akaza, T. Niijima, K. Koseki, 2004, Urological Research.

Testicular cancers occurring in brothers with cryptorchism

H. Akaza, K. Kawai, N. Sekido, 2002, International journal of urology : official journal of the Japanese Urological Association.

[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].

S. Ishikawa, N. Miyanaga, H. Akaza, 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Practice Manual for Late‐onset Hypogonadism Syndrome

H. Akaza, T. Yanase, Hiroaki Kumano, 2008, International journal of urology : official journal of the Japanese Urological Association.

Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group.

T. Miki, H. Akaza, O. Yoshida, 1992, Cancer chemotherapy and pharmacology.

Significance of UICC Activities in Global Health Initiatives on Cancer Looking Towards the Future of Cooperative Networks for Cancer Care in Asia - A Dialogue with the Union for International Cancer Control(UICC).

H. Akaza, Norie Kawahara, Cary Adams, 2017, Gan to kagaku ryoho. Cancer & chemotherapy.